What Are the Regulatory Requirements for CCIT Sampling?
Container Closure Integrity Testing (CCIT) sampling for sterile injectable release sits at the intersection of several regulatory frameworks. Understanding how they fit together allows manufacturers to build sampling plans that are both scientifically sound and submission-ready.
What does USP <1207> require?
USP <1207> is the primary US standard for package integrity evaluation of sterile products. It requires a validated, scientifically justified CCI method and a documented rationale for the sampling approach — including its statistical basis. It does not prescribe specific sample sizes, but it expects the plan to be defensible in terms of what it can and cannot detect.
How does ICH Q9 shape sampling philosophy?
ICH Q9 Quality Risk Management provides the foundational principle: the extent of sampling should be proportionate to the risk to the patient. For sterile injectables, a compromised closure is a patient safety event. This directly supports conservative c = 0 sampling and the stratified architectures described for multi-head automated processes.
What does EU GMP Annex 1 expect?
The 2022 revision of Annex 1 requires CCI to be addressed within the facility's Contamination Control Strategy (CCS). Sampling plans must be documented, cover the full manufacturing process (not a convenient subset), and carry a risk-proportionate justification. Annex 1 also specifies 100% CCI testing requirements for BFS products — a distinct requirement outside the scope of standard AQL release sampling.
What standard underpins the sample size tables?
ANSI/ASQ Z1.4 provides the statistical framework for attribute sampling by lot size. Citing this standard in quality documentation and regulatory submissions provides immediate traceability for the sampling logic. All sample sizes in this guidance are derived from Z1.4 General Inspection Level II, c = 0.
What language positions a sampling plan in a regulatory submission?
"CCI release testing is performed using a validated deterministic method per USP <1207>. Sample sizes follow AQL principles aligned with ANSI/ASQ Z1.4 General Inspection Level II, c = 0, with stratified sampling ensuring coverage of all production time segments and crimping stations. This approach is consistent with ICH Q9 quality risk management principles and EU GMP Annex 1."
This language is concise, cites the right standards, and directly addresses the regulatory expectation for risk-proportionate, scientifically justified sampling.